#France #HTL Biotechnology #Javené #Polynucleotides

HTL Biotechnology Launches HTL8

On November 12, HTL Biotechnology, a leading innovator in the field of biopolymers, inaugurated its latest production unit, HTL8, situated at its facility in Javené, Ille-et-Vilaine, France. This significant milestone highlights the company's commitment to enhancing its portfolio and expanding its global reach, particularly in the booming market for pharmaceutical-grade biopolymers.

HTL8 represents a €15 million investment, part of the company's broader strategy to invest €100 million from 2022 to 2026. This ambitious plan aims to diversify HTL's product range and align with the increasing global demand for high-quality biopolymers used in demanding therapeutic applications.

For 45 years, HTL Biotechnology has been a forerunner in the production of cutting-edge polynucleotides, which are essential in regenerative medicine. Polynucleotides, composed of nucleotide chains, are recognized for their regenerative properties that enhance tissue repair, moisture retention, and skin quality improvement, essential for medical aesthetics and dermatology.

At the heart of HTL's production process are high-quality biopolymers derived from DNA obtained from wild Alaskan salmon milt, a sustainable byproduct of the salmon industry. This innovative practice ensures a reliable source of pharmaceutical raw materials while promoting environmental sustainability.

The HTL8 facility is designed to fulfill stringent pharmaceutical manufacturing standards, integrating advanced technologies and automation. It emphasizes robust quality control and adherence to safety regulations, steering HTL Biotechnology towards its goal of being a leading player in health innovation.

François Fournier, CEO of HTL Biotechnology, stated that HTL8 embodies the company’s vision for industrial excellence, equipped with state-of-the-art technology. He emphasized the commitment to understanding market demands and customer expectations, ensuring a proactive approach to industry growth. "HTL8 anchors our capabilities in France while enabling us to meet global standards and fulfill our ambition to provide innovative pharmaceutical solutions," Fournier mentioned.

HTL Biotechnology is not only dedicated to the present needs of the healthcare industry but is also positioning itself for future advancements by focusing on new applications of its products, particularly in regenerative medicine and therapeutic fields such as ophthalmology and wound healing.

The establishment of HTL8 is a crucial step in supporting HTL Biotechnology's growth trajectory while reinforcing its leadership in the biopolymer sector. With nearly 300 employees globally and a commitment to research and development, HTL is poised to continue its legacy of innovation in pharmaceutical biotechnology.

For more insights, please visit HTL Biotechnology's official website or connect with them on LinkedIn.